Clearside Biomedical Finds the Public Markets Despite Diminished Interest in Sector

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 096″]

Clearside CEO Dan White says the days when ophthalmology IPO candidates could do no wrong are over. Still, the company staged a successful IPO to help further development of its SCS microinjector technology.